Migraine - Pipeline Review, H1 2012

Migraine – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Migraine - Pipeline Review, H1 2012', provides an overview of the Migraine therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. 'Migraine - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Migraine.
• A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Migraine pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Migraine.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Migraine therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Migraine Overview
Therapeutics Development
An Overview of Pipeline Products for Migraine
Migraine Therapeutics under Development by Companies
Migraine Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Migraine Therapeutics – Products under Development by Companies
Migraine Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Migraine Therapeutics Development
Sanofi-Aventis
Vyteris, Inc.
Eli Lilly and Company
Vectura Group plc
Biofrontera AG
Novartis AG
Axcan Pharma Inc.
Eisai Co., Ltd.
Pfizer Inc.
Teva Pharmaceutical Industries Limited
NuPathe Inc.
Capnia, Inc.
IntelGenx Technologies Corp.
NovaDel Pharma, Inc.
Paladin Labs Inc.
MAP Pharmaceuticals, Inc.
POZEN Inc.
Asterand plc.
Genizon BioSciences, Inc.
D-Pharm Ltd.
Physica Pharma
MIKA Pharma GmbH
Ache Laboratorios Farmaceuticos S/A
CoLucid Pharmaceuticals, Inc.
Pantarhei Bioscience BV
NeurAxon, Inc.
Winston Pharmaceuticals, Inc.
The EMMES Corporation
Trigemina, Inc.
Migraine – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
E2007 - Drug Profile
Levadex - Drug Profile
EUR 1000 - Drug Profile
BF-1 - Drug Profile
MK49 - Drug Profile
Sumatriptan SDI - Drug Profile
PHY 303 - Drug Profile
Estetrol - Drug Profile
INT0008 - Drug Profile
Zolmitriptan - Drug Profile
MT 400 - Drug Profile
NXN-188 - Drug Profile
NXN-462 - Drug Profile
nNOS/NET - Drug Profile
VR147 - Drug Profile
Nasal Carbon Dioxide - Drug Profile
NVD-201 - Drug Profile
DP-VPA - Drug Profile
Candesartan Cilexitil - Drug Profile
BGG492 - Drug Profile
TI-001 - Drug Profile
PF-04427429 - Drug Profile
LY2951742 - Drug Profile
Metoclopramide - Drug Profile
Topiramate - Drug Profile
Sodium Valporate - Drug Profile
Zelrix - Drug Profile
Enalapril - Drug Profile
COL-144 - Drug Profile
Topiramate + Propranolol - Drug Profile
N-Alpha Methyl Histamine - Drug Profile
Compazine - Drug Profile
Ethosuximide - Drug Profile
Metoclopramide + Ketoprofen - Drug Profile
BGC20-1531 - Drug Profile
Caffeine + Propranolol - Drug Profile
Longevity Program - Drug Profile
DR-105 - Drug Profile
Ketoprofen - Drug Profile
Cyclobenzaprine Hydrochloride Extended Release - Drug Profile
Dolorac - Drug Profile
LY2300559 - Drug Profile
Propofol - Drug Profile
Dexamethasone - Drug Profile
DIS-COM-TRO - Drug Profile
RHB-103 - Drug Profile
R101 - Drug Profile
Simvastatin + Vitamin D - Drug Profile
Naratriptan + Naproxen - Drug Profile
Topiramate - Drug Profile
Topiramate - Drug Profile
Ibuprofen + Caffeine - Drug Profile
Migraine Therapeutics – Drug Profile Updates
Migraine Therapeutics – Discontinued Products
Migraine Therapeutics - Dormant Products
Migraine – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Migraine, H1 2012
Products under Development for Migraine – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Sanofi-Aventis, H1 2012
Vyteris, Inc., H1 2012
Eli Lilly and Company, H1 2012
Vectura Group plc, H1 2012
Biofrontera AG, H1 2012
Novartis AG, H1 2012
Axcan Pharma Inc., H1 2012
Eisai Co., Ltd., H1 2012
Pfizer Inc., H1 2012
Teva Pharmaceutical Industries Limited, H1 2012
NuPathe Inc., H1 2012
Capnia, Inc., H1 2012
IntelGenx Technologies Corp., H1 2012
NovaDel Pharma, Inc., H1 2012
Paladin Labs Inc., H1 2012
MAP Pharmaceuticals, Inc., H1 2012
POZEN Inc., H1 2012
Asterand plc., H1 2012
Genizon BioSciences, Inc., H1 2012
D-Pharm Ltd., H1 2012
Physica Pharma, H1 2012
MIKA Pharma GmbH, H1 2012
Ache Laboratorios Farmaceuticos S/A, H1 2012
CoLucid Pharmaceuticals, Inc., H1 2012
Pantarhei Bioscience BV, H1 2012
NeurAxon, Inc., H1 2012
Winston Pharmaceuticals, Inc., H1 2012
The EMMES Corporation, H1 2012
Trigemina, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Migraine Therapeutics – Drug Profile Updates
Migraine Therapeutics – Discontinued Products
Migraine Therapeutics – Dormant Products

LIST OF FIGURES

Number of Products under Development for Migraine, H1 2012
Products under Development for Migraine – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012 Skip to top